Boris Kantor

Florida State University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index1.9kcitations57works8.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(25), Virus-based gene therapy research(17), Epigenetics and DNA Methylation(11), Pluripotent Stem Cells Research(6), RNA Interference and Gene Delivery(6)

Publications57 total

CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges
Molecular Therapy — Nucleic Acids·2025Open Access
Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease
Molecular Therapy — Nucleic Acids·2025· 13 citedOpen Access
<i>SNCA</i> -targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse model
2025Open Access
The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders
Nature Communications·2024· 21 citedOpen Access
APOE‐targeted epigenome therapy for late onset Alzheimer’s disease
Alzheimer s & Dementia·2023· 1 citedOpen Access
Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies
Molecular Therapy — Nucleic Acids·2023· 17 citedOpen Access
All-in-one AAV-delivered epigenome-editing platform: <i>proof-of-concept</i> and therapeutic implications for neurodegenerative disorders
2023· 4 citedOpen Access
<i>APOE</i>‐targeted epigenome therapy for late onset Alzheimer’s disease
Alzheimer s & Dementia·2022· 4 cited
Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs
Frontiers in Bioengineering and Biotechnology·2022· 33 citedOpen Access
Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives
Viruses·2021· 128 citedOpen Access
Cell-Type Specific Changes in DNA Methylation of SNCA Intron 1 in Synucleinopathy Brains
Frontiers in Neuroscience·2021· 29 citedOpen Access
Adeno-Associated Virus-Mediated Gene Therapy in the Mashlool, <i> Atp1a3 <sup>Mashl/+</sup> </i> , Mouse Model of Alternating Hemiplegia of Childhood
Human Gene Therapy·2021· 19 citedOpen Access
APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer’s
International Journal of Molecular Sciences·2021· 43 citedOpen Access
The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models
Molecular Therapy·2021· 23 citedOpen Access
Lentiviral vectors as the delivery vehicles for transduction into iPSCs
Elsevier eBooks·2021· 1 cited
Contributors
Elsevier eBooks·2021
Allele specific targeting of APOE‐E4 expression: The novel CRISRP/CAS9‐based platform for precision therapy for Alzheimer’s disease
Alzheimer s & Dementia·2020Open Access
AAV Exploits Subcellular Stress Associated with Inflammation, Endoplasmic Reticulum Expansion, and Misfolded Proteins in Models of Cystic Fibrosis
UNC Libraries·2020Open Access
Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
UNC Libraries·2020Open Access
A Large U3 Deletion Causes Increased In Vivo Expression From a Nonintegrating Lentiviral Vector
UNC Libraries·2020Open Access
page 1 of 3Next →

Frequent Co-authors

Ornit Chiba‐Falek(17), Tal Kafri(8), Aharon Razin(7), Joseph E. Rittiner(7), Bernadette O’Donovan(6), Wendy Dong(5), Lidia Tagliafierro(4), Jeffrey Gu(4), Ekaterina Ilich(4), Susan K. Murphy(4), Thomas J. McCown(4), Malik Moncalvo(4), Ruth Shemer(4), Carole Grenier(3), R. Jude Samulski(3), Hong Ma(3), Brian Zeithaml(3), Dellila Hodgson(3), Vladislav Temkin(2), Mor-Li Hartman(2)